• D&D Pharmatech agreed to acquire intellectual property for three drug pipelines from wholly owned U.S. subsidiary Neuraly for USD 3.31 million.
• The transfer, effective Nov. 2, 2026, gives the parent ownership and exclusive development and commercialization rights.
• The pipelines comprise TLY012 for fibrosis, NLY01 for neurodegenerative diseases and NLY12 for metabolic diseases.
• No subsequent royalties are payable between the companies. An independent specialist valued the assets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. D&D Pharmatech Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102900320), on November 02, 2026, and is solely responsible for the information contained therein.